Phosphorex

Phosphorex is a leading CDMO with over 18 years of experience in sustained-release formulation, nanomedicine, and nucleic acid delivery. With Phosphorex’s expertise and innovative technologies, our team excels in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Based in Hopkinton, MA, our cutting-edge CDMO facility encompasses an impressive 30,000 sq. ft. of lab space, with a cGMP facility coming online in late 2024. Phosphorex is owned by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.